Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Study of SHR6390 in Renal Insufficiency and Healthy Subjects
NCT05515289Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Dec 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of dalpiciclib in breast cancer (3 arms), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time zero to last measurable concentration and 1 more. Status: unknown.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05515289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05515289.